In Silico Study of Innovative Compounds Targeting Protein (Survivin): Understandings into Cancer Therapeutics

Abdullah Hamadi, Hyfa Alzahrani, Fawzyah Albaldi, Sallwa M Alshehre, Ali Mahzari

Abstract


Background: Survivin, also known as Baculoviral Inhibitor of Apoptosis Repeat Containing 5 (BIRC5), is a key protein involved in cell division and the inhibition of apoptosis, making it an essential component of eukaryotic cell biology. Survivin is highly expressed across all human tumor lines and is significant in cancer due to its dual function in promoting cell proliferation and inhibiting apoptosis. Programmed cell death (PCD) is critical for mammalian development and disease regulation. The dysregulation of apoptosis leads to uncontrolled cell proliferation, which contributes to tumor progression and metastasis. Survivin interacts with caspases, predominantly inhibiting Caspase-3 and Caspase-7, thereby playing a key role in dysregulating apoptosis. Given its preferential expression in tumor cells and its decisive role in carcinogenesis and chemoresistance, Survivin emerges as an attractive target for cancer treatment.

Methods: Compounds from the PubChem database were screened using molecular docking. Lead candidates were then evaluated for drug-likeness and ADMET properties, and the stability of the top compound-protein complex was analyzed using molecular dynamics simulations.

Results: The current study highlights the therapeutic potential of novel compounds designed to inhibit Survivin in cancer therapy. This probability is illuminated through the use of innovative techniques such as computer-generated (virtual) screening and molecular docking. The lead compounds have also been filtered for their drug-likeness and ADMET potential.

Conclusion: The stability of the designated compounds has been investigated in-depth through MD simulations. The results from this study suggest that the compound CID:155104111 (1-[2-(difluoromethoxy)ethyl]-2-methyl-3-(pyrazin-2-ylmethyl)benzo[f]benzimidazol-3-ium-4,9-dione) is a potential lead candidate for targeting the Survivin protein, showing promise when compared to the standard inhibitor, YM155.

Keywords: Survivin; Apoptosis; Caspases; YM155; PubChem; Molecular Dynamics


Full Text:

PDF

References


Blanco Wheatley SP, , Altieri DC. Survivin at a glance. Journal of Cell Science, (2019); 132(7), jcs223826.

Martínez-Sifuentes MA, Bassol-Mayagoitia S, Nava-Hernández MP, Ruiz-Flores P, Ramos-Treviño J, et al. Survivin in Breast Cancer: A Review. Genetic Testing and Molecular Biomarkers , (2022); 26(9): 411-421.

Shojaei F, Yazdani-Nafchi F, Banitalebi-Dehkordi M, Chehelgerdi M, Khorramian-Ghahfarokhi M. Trace of Survivin in cancer. European Journal of Cancer Prevention. (2019); 28(4): 365-372.

Shomali N, Suliman Maashi M, Baradaran B, Daei Sorkhabi A, Sarkesh A, et al. Dysregulation of Survivin-Targeting microRNAs in Autoimmune Diseases: New Perspectives for Novel Therapies. Frontiers in Immunology. (2022); 13: 839945.

Bernardo PS, Lemos LGT, de Moraes GN, Maia RC. Unraveling Survivin expression in chronic myeloid leukemia: Molecular interactions and clinical implications. Blood Reviews. (2020); 43: 100671.

Lyu H, Huang J, He Z, Liu B. Epigenetic mechanism of Survivin dysregulation in human cancer. Science China Life Sciences. (2018); 61(7): 808-814.

Duffy MJ, O'Donovan N, Brennan DJ, Gallagher WM, Ryan BM. Survivin: a promising tumor biomarker. Cancer Letters. (2007); 249(1): 49-60.

Braný D, Dvorská D, Kúdela E, Danková Z, Halášová E, Višňovský J. Potential of Survivin for treatment of gynaecological tumour diseases. Ceska gynekologie. (2018); 83(3): 226-231.

Warrier NM, Agarwal P, Kumar P. Emerging Importance of Survivin in Stem Cells and Cancer: the Development of New Cancer Therapeutics. Journal of Haematology and Stem Cell Research. (2020); 16(5): 828-852.

Li F. Survivin study: what is the next wave? Journal of cellular physiology, (2003);197(1): 8-29.

Altieri DC. Validating Survivin as a cancer therapeutic target. Nature reviews Cancer, (2003); 3(1):46-54.

Fang XL, Cao XP, Xiao J, Hu Y, Chen M, et al. Overview of role of Survivin in cancer: expression, regulation, functions, and its potential as a therapeutic target. Journal of Drug Targeting, (2024); 32(3): 223-240.

Santarelli A, Mascitti M, Lo Russo L, Sartini D, Troiano G, et al. Survivin-Based Treatment Strategies for Squamous Cell Carcinoma. International Journal of Molecular Sciences, (2018); 19(4): 971

Albadari N, , Li W. Survivin small molecules inhibitors: Recent advances and challenges. Molecules, (2023); 28(3): 1376.

Warrier NM, Agarwal P, Kumar P. Emerging importance of Survivin in stem cells and cancer: The development of new cancer therapeutics. tem Cell Reviews and Reports. (2020); 16(5): 828-852.

Mahmoudian-Sani M, Alghasi A, Saeedi-Boroujeni A, Jalali A, Jamshidi M, Khodadadi A. Survivin as a diagnostic and therapeutic marker for thyroid cancer. Pathology Research and Practice, (2019); 215(4): 619-625.

Li F, Aljahdali I, Ling X. Cancer therapeutics using Survivin BIRC5 as a target: what can we do after over two decades of study. Journal of Experimental , Clinical Cancer Research, (2019); 38, 368.

Babkoff A, Cohen-Kfir E, Aharon H, Ronen D, Rosenberg M, et al. A direct interaction between Survivin and myosin II is required for cytokinesis. Journal of Cell Science, (2019); 132(14): jcs233130.

Park S-H, Shin I, Park S-H, Kim ND, Shin I. An Inhibitor of the Interaction of Survivin with Smac in Mitochondria Promotes Apoptosis. Chemistry - An Asian Journal, (2019); 14(22), 4035-4041.

Sarvagalla S, Lin T, Kondapuram SK, Cheung CHA, Coumar MS. Survivin - caspase protein-protein interaction: Experimental evidence and computational investigations to decipher the hotspot residues for drug targeting. Journal of Molecular Structure, (2021); 1229(4): 129619.

Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, et al. STRING v11: Protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Research, (2019); 47(D1).

Martínez‐García D, Manero‐Rupérez N, Quesada R, Korrodi‐Gregório L, , Soto‐Cerrato V. Therapeutic strategies involving Survivin inhibition in cancer. Medicinal Research Reviews, (2019); 39(3): 887-909.

Wang Q, Arnst K, Xue Y, Lei Z, Ma D, et al. Synthesis and biological evaluation of indole-based UC-112 analogs as potent and selective Survivin inhibitors. European Journal of Medicinal Chemistry, (2018); 149: 211-224.

Yu X, Zhang Y, Cavazos D, Ma X, Zhao Z, et al. MiR-195 targets cyclin D3 and Survivin to modulate the tumorigenesis of non-small cell lung cancer. Cell Death and Disease, (2018); 9(2): 193.

Vay C, Babaei S, Safi S, Dizdar L, Rehders A, et al. Clinicopathological and prognostic value of Survivin expression in surgically resected pancreatic ductal adenocarcinoma. Cancers, (2022); 14(14): 3494.

Adamopoulos P, Tsiakanikas P, Adam E, , Scorilas A. Unraveling novel Survivin mRNA transcripts in cancer cells using an in-house developed targeted high-throughput sequencing approach. Genomics, (2021); 113(1): 573-581.

Lv X, Jiang Y, Wang X, Xie H, Dou G, et al. Computational study on novel natural inhibitors targeting BCL2. Medical Oncology, (2021); 38(8): 94.

Komura H, Watanabe R, Mizuguchi K. The Trends and Future Prospective of In Silico Models from the Viewpoint of ADME Evaluation in Drug Discovery. Pharmaceutics, (2023); 15(11): 2619.

Shou WZ. Status and future directions of high-throughput ADME screening in drug discovery. Journal of Pharmaceutical Analysis, (2020); 10(4): 1.

Daoud N, Borah P, Deb P, Venugopala K, Hourani W, et al. ADMET Profiling in Drug Discovery and Development: Perspectives of In Silico, In Vitro and Integrated Approaches. Current Drug Metabolism, (2021); 22(7), 503-522.

Zhong S, Zhang Z, Guo Z, Yang W, Dou G, et al. Identification of novel natural inhibitors targeting AKT Serine/Threonine Kinase 1 (AKT1) by computational study. Bioengineered. (2022); 13(5): 12003-12020.

Raja T, Ravikumar P, Srinivasan MR, Vijayarani K, Kumanan K. Identification of Potential Novel Inhibitors for Nipah Virus – An in-silico Approach International Journal of Current Microbiology and Applied Sciences. (2020); 9(9): 3377-3390.

Jia C-Y, Li J-Y, Hao G-F, Yang G-F. A drug-likeness toolbox facilitates ADMET study in drug discovery. Drug Discovery Today, (2020); 25(1): 248-258.

Barbhuiya S, Das BB. Molecular dynamics simulation in concrete research: A systematic review of techniques, models, and future directions. Journal of Building Engineering, (2023); 107267.

Ghosh S, Chetia D, Gogoi N, Rudrapal M. Design, molecular docking, drug-likeness, and molecular dynamics studies of 1,2,4-trioxane derivatives as novel plasmodium falciparum falcipain-2 (Fp-2) inhibitors. Biotechnologia, (2021); 102(3): 257-275.

Raychaudhury C, Srinivasan S, Pal D. Identification of potential oral cancer drugs as Bcl-2 inhibitors from known anti-neoplastic agents through docking studies. Journal of Mathematical Chemistry, (2024); 62(2): 317-329.

Liu N, Wang X, Wu H, Lv X, Xie H, et al. Computational study of effective matrix metalloproteinase 9 (MMP9) targeting natural inhibitors. Aging, (2021); 13(19). 22867–22882.

Ferreira LLG, Andricopulo AD. ADMET modeling approaches in drug discovery. Drug Discovery Today, (2019); 24(5): 1157-1165.

Adelusi TI, Oyedele A-QK, Boyenle ID, Ogunlana AT, Adeyemi RO, et al. Molecular modeling in drug discovery. Informatics in Medicine Unlocked, (2022);29. 100880.

Papaleo E, Saladino G, Lambrughi M, Lindorff-Larsen K, Gervasio FL. The role of protein loops and linkers in conformational dynamics and allostery. Chemical Society Reviews, (2016); 45(22), 22-42.

Roe DR, Cheatham III TE. PTRAJ and CPPTRAJ: software for processing and analysis of molecular dynamics trajectory data. Journal of chemical theory and computation, (2013); 9(7): 3084-3095.

Gapsys V, de Groot BL, Briones R. Quantifying flexibility in protein structures: comparison of experimental and theoretical B-factor distributions. Biophysical journal, (2015); 108(10): 2585-2595.

Zhong Q, Qin J, Zhao K, Guo L, Li D. Molecular Docking and Molecular Dynamics Simulation of New Potential JAK3 Inhibitors. Current Computer-Aided Drug Design, (2023); 20 (6): 764-772.

Miao H, Klein T, Kouřil D, Mindek P, Schatz K, et al. Multiscale Molecular Visualization. Journal of Molecular Biololgy, (2019); 431(6):1049-1070.

Sargsyan K, Grauffel C, Lim C. How Molecular Size Impacts RMSD Applications in Molecular Dynamics Simulations. Journal of Chemical Theory and Computation, (2017); 13(4): 1518-1524.

Laasonen K. Ab initio molecular dynamics. Methods in Molecular Biology, (2013); 924: 29-42.

Giodini A, Kallio MJ, Wall NR, Gorbsky GJ, Tognin S, et al. Regulation of microtubule stability and mitotic progression by Survivin. Cancer Research, (2002); 62(9): 2462-2467.

Lv Y-G, Yu F, Yao Q, Chen JH, Wang L. Role of Survivin in diagnosis, prognosis, and treatment of breast cancer. Journal of Thoracic Disease, (2010); 2(2): 100-110.

Savitskaya MA, Onishchenko GE. Mechanisms of Apoptosis. Biochemistry, (2015); 80(11): 1393-405.




DOI: http://dx.doi.org/10.62940/als.v12i2.3454

Refbacks

  • There are currently no refbacks.